| Title | Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE. | | Author(s) | de la Fouchardière C, Largillier R, Goubely Y, Hardy-Bessard AC, Slama B, Cretin J, Orfeuvre H, Paraiso D, Bachelot T, Pujade-Lauraine E | | Institution | Department of Medical Oncology, Centre Léon Bérard, Lyon. | | Source | Ann Oncol 2009 Jun 25. | | Abstract | BACKGROUND: This phase II study evaluated the clinical benefit of pegylated liposomal doxorubicin (PLD) and docetaxel (Taxotere) as first-line therapy for metastatic breast cancer (MBC).
PATIENTS AND METHODS: MBC patients were enrolled to receive six cycles of PLD 35 mg/m(2) (day 1) and docetaxel 40 mg/m(2) (days 1 and 15), every 28 days (group A). Because of unacceptable toxic effects, doses were modified to PLD 30 mg/m(2) (day 1) and docetaxel 75 mg/m(2) (day 2), every 3 weeks (group B). The primary end point was clinical benefit.
RESULTS: Sixty-seven patients were included (group A, 53; group B, 14). In both groups, the median number of cycles delivered was 4 and the overall dose intensity was 82% for docetaxel and 71% for PLD. In group A, main toxic effects were hematologic, palmar-plantar erythrodysesthesia (PPE), and stomatitis. In group B, higher rates of grade 3-4 PPE, febrile neutropenia, and hematologic toxic effects were reported. The rate of clinical benefit was 47%. Among patients with a measurable disease, 49% achieved a partial response, 27% had a stable disease, and 13% progressed, according to RECIST criteria.
CONCLUSION: The combination of PLD and docetaxel delivered at planned doses in this study yields unacceptable toxicity and should not be used routinely in patients with MBC. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19556321 |
|
